688796 百奥赛图
已收盘 03-31 15:00:00
资讯
新帖
简况
净利跑出416%增速，百奥赛图-B(02315)迎来商业化兑现期
智通财经 · 03-30 09:06
净利跑出416%增速，百奥赛图-B(02315)迎来商业化兑现期
每周股票复盘：百奥赛图（688796）2025年归母净利润1.73亿元，同比上升416.37%
证券之星 · 03-29
每周股票复盘：百奥赛图（688796）2025年归母净利润1.73亿元，同比上升416.37%
百奥赛图（688796）披露合作伙伴双抗ADC药物获FDA临床试验批准，3月27日股价上涨12.68%
证券之星 · 03-27
百奥赛图（688796）披露合作伙伴双抗ADC药物获FDA临床试验批准，3月27日股价上涨12.68%
百奥赛图涨12.68%，信达证券二个月前给出“买入”评级
证券之星 · 03-27
百奥赛图涨12.68%，信达证券二个月前给出“买入”评级
港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长
智通财经 · 03-27
港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长
百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可，合作迈入关键里程碑
智通财经 · 03-26
百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可，合作迈入关键里程碑
百奥赛图（688796）披露2025年年度报告，3月26日股价下跌2.82%
证券之星 · 03-26
百奥赛图（688796）披露2025年年度报告，3月26日股价下跌2.82%
百奥赛图(688796.SH)：2025年归母净利润1.73亿元，同比增加416.37%
中金财经 · 03-26
百奥赛图(688796.SH)：2025年归母净利润1.73亿元，同比增加416.37%
港股百奥赛图-B涨超12%
每日经济新闻 · 03-24
港股百奥赛图-B涨超12%
港股异动 | 百奥赛图-B(02315)涨超12% 与Moonlight Bio达成战略合作 去年纯利同比预增超四倍
智通财经 · 03-24
港股异动 | 百奥赛图-B(02315)涨超12% 与Moonlight Bio达成战略合作 去年纯利同比预增超四倍
百奥赛图与合作伙伴达成协议，将提供针对治疗靶点的现货抗体结合剂
美股速递 · 03-23
百奥赛图与合作伙伴达成协议，将提供针对治疗靶点的现货抗体结合剂
百奥赛图宣布与Moonlight Bio达成战略合作，利用全人抗体分子库推进细胞疗法开发
美通社 · 03-23
百奥赛图宣布与Moonlight Bio达成战略合作，利用全人抗体分子库推进细胞疗法开发
百奥赛图-B盘中涨超7%
每日经济新闻 · 03-16
百奥赛图-B盘中涨超7%
港股异动 | 百奥赛图-B(02315)盘中涨超7% 预计全年纯利同比增超4倍 重磅合作项目顺利推进
智通财经 · 03-16
港股异动 | 百奥赛图-B(02315)盘中涨超7% 预计全年纯利同比增超4倍 重磅合作项目顺利推进
港股医药股多数走强 百奥赛图涨近10%
南方财经网 · 03-10
港股医药股多数走强 百奥赛图涨近10%
每周股票复盘：百奥赛图（688796）H股A股股本无变动
证券之星 · 03-08
每周股票复盘：百奥赛图（688796）H股A股股本无变动
港股异动 | 百奥赛图-B(02315)涨超8% 预计25年归母净利同比增超4.16倍 商业化提速打开成长空间
智通财经 · 03-06
港股异动 | 百奥赛图-B(02315)涨超8% 预计25年归母净利同比增超4.16倍 商业化提速打开成长空间
百奥赛图（688796）披露证券变动月报表，3月4日股价下跌0.43%
证券之星 · 03-04
百奥赛图（688796）披露证券变动月报表，3月4日股价下跌0.43%
每周股票复盘：百奥赛图（688796）2025年净利增416.37%
证券之星 · 03-01
每周股票复盘：百奥赛图（688796）2025年净利增416.37%
百奥赛图达成临床里程碑：IDEAYA首创B7h3/Ptk7双特异性Top1 ADC药物Ide034完成首例患者给药
美股速递 · 02-28
百奥赛图达成临床里程碑：IDEAYA首创B7h3/Ptk7双特异性Top1 ADC药物Ide034完成首例患者给药
加载更多
公司概况
公司名称：
百奥赛图(北京)医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2025-12-10
主营业务：
百奥赛图(北京)医药科技股份有限公司的主营业务是基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务。公司的主要产品是基因编辑服务、创新模式动物销售、临床前药理药效评价服务、抗体开发、创新药合作研发。公司全面的创新模式动物产品和大规模动物生产与体内外药效研究相结合，可为全球生物技术及大型制药公司客户提供疾病模式动物和体内药理服务。
发行价格：
26.68
{"stockData":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"百奥赛图","latestPrice":93.02,"timestamp":1774940400000,"preClose":93.9,"halted":0,"volume":2785868,"delay":0,"changeRate":-0.0094,"floatShares":35887600,"shares":447000000,"eps":0.7001,"marketStatus":"已收盘","change":-0.88,"latestTime":"03-31 15:00:00","open":92.9,"high":95.72,"low":88.7,"amount":254000000,"amplitude":0.0748,"askPrice":93.02,"askSize":24,"bidPrice":93.01,"bidSize":11,"shortable":0,"etf":0,"ttmEps":0.7001,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775007000000},"marketStatusCode":5,"adr":0,"adjPreClose":93.9,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774920600000,1774927800000],[1774933200000,1774940400000]],"highLimit":103.29,"lowLimit":84.51,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446898420,"isCdr":false,"pbRate":19.11,"roa":"--","peRate":132.866733,"roe":"16.85%","epsLYR":0.43,"committee":0.85504,"marketValue":41570000000,"turnoverRate":0.0776,"status":1,"afterMarket":{"amount":0,"volume":0,"close":93.02,"buyVolume":729,"sellVolume":0,"time":1774942437558,"indexStatus":"已收盘 03-31 15:30:00","preClose":93.9},"hkstockBrief":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":55.35,"timestamp":1774944505004,"preClose":57.25,"halted":0,"volume":878892,"delay":0,"premium":"-47.72"},"floatMarketCap":3338000000},"requestUrl":"/m/hq/s/688796","defaultTab":"news","newsList":[{"id":"2623612963","title":"净利跑出416%增速，百奥赛图-B(02315)迎来商业化兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2623612963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623612963?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:06","pubTimestamp":1774832793,"startTime":"0","endTime":"0","summary":"2026年，创新药板块迎来多重利好共振，行业回暖态势明确。2025年，公司模式动物业务收入6.22亿元，同比增长近60%，毛利率超80%，持续贡献稳定现金流。2025年，百奥赛图抗体开发业务实现收入3.32亿元，毛利率达86%;累计签署超350项合作协议，其中2025年就新增150余项。短期业绩利好催化股价上行，叠加长期价值逐步显现，百奥赛图凭借其创新技术、稀缺的商业模式与全球新药研发体系中的有利卡位，有望率先受益于行业景气度回升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","BK1161","BK0216","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623380506","title":"每周股票复盘：百奥赛图（688796）2025年归母净利润1.73亿元，同比上升416.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623380506","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623380506?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:58","pubTimestamp":1774720688,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百奥赛图报收于92.88元，较上周的77.4元上涨20.0%。业绩披露要点百奥赛图2025年主营收入13.79亿元，同比上升40.63%；归母净利润1.73亿元，同比上升416.37%；扣非净利润1.16亿元，同比上升405.39%。2025年第四季度单季度主营收入4.38亿元，同比上升12.12%；单季度归母净利润5907.3万元，同比下降56.5%；单季度扣非净利润5830.72万元，同比下降51.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820586","title":"百奥赛图（688796）披露合作伙伴双抗ADC药物获FDA临床试验批准，3月27日股价上涨12.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820586","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622820586?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:08","pubTimestamp":1774620504,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百奥赛图报收于92.88元，较前一交易日上涨12.68%，最新总市值为415.08亿元。该股当日开盘82.19元，最高93.17元，最低81.19元，成交额达2.58亿元，换手率为8.1%。近日，百奥赛图发布港股自愿性公告披露：其合作伙伴NEOK Bio的双抗ADC药物NEOK002获得美国FDA的新药临床试验批准，该药物靶向EGFR/MUC1，用于实体瘤治疗。NEOK Bio计划于2026年第二季度启动I期临床试验，预计2027年公布初步临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700049333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873849","title":"百奥赛图涨12.68%，信达证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873849?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:14","pubTimestamp":1774599266,"startTime":"0","endTime":"0","summary":"今日百奥赛图涨12.68%，收盘报92.88元。2026年1月9日，信达证券研究员唐爱金,贺鑫发布了对百奥赛图的研报《公司深度报告：高速成长的生物技术平台，乘风破浪未来可期》，该研报对百奥赛图给出“买入”评级。我们认为百奥赛图是全球领先的生物技术平台型公司，RenMice平台有望贡献高弹性空间，BioMice平台有望贡献稳定现金流，中长期成长性突出，首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622045816","title":"港股异动 | 百奥赛图-B(02315)涨超12% 全年纯利同比增超4倍 海外业务实现快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622045816","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622045816?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:39","pubTimestamp":1774579145,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超12%，截至发稿，涨11.99%，报60.25港元，成交额7808.72万港元。消息面上，百奥赛图发布2025年度业绩，公司实现营业收入13.79亿元，同比增长40.63%，归母净利润1.73亿元，同比增长416.37%，扣非净利润1.16亿元，同比增长405.39%。值得关注的是，百奥赛图全球化布局成果卓越，2025年海外收入占比近70%，服务网络覆盖美国，欧洲和亚太市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","VXUS","BK0216","BK1161","688796","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622986952","title":"百奥赛图-B(02315)合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可，合作迈入关键里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2622986952","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622986952?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:35","pubTimestamp":1774535741,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥赛图-B 发布公告，本公司合作伙伴NEOK Bio, Inc.近日获得美国食品药品监督管理局对其在研新药NEOK002的新药临床试验申请批准。NEOK Bio计划于2026年第二季度启动I期临床试验，并预计于2027年公布初步临床数据。此次IND获批标志着NEOK002项目取得重要里程碑进展。NEOK002基于百奥赛图自主开发并于2024年对外授权的双特异性抗体构建，由NEOK Bio进一步推进 ADC药物开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4080","BK4231","BK1161","LABU","BK0216","02315","ADC","688796","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622002866","title":"百奥赛图（688796）披露2025年年度报告，3月26日股价下跌2.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002866","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622002866?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:25","pubTimestamp":1774535120,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，百奥赛图报收于82.43元，较前一交易日下跌2.82%，最新总市值为368.38亿元。近日，百奥赛图（北京）医药科技股份有限公司披露《2025年年度报告》。公告显示，公司2025年实现营业收入137,880.84万元，同比增长40.63%；归属于上市公司股东的净利润为17,319.98万元，同比增长416.37%；归属于上市公司股东的扣除非经常性损益的净利润为11,607.78万元，同比增长405.39%。利润总额为18,803.05万元，同比增长337.90%。研发投入占营业收入的比例为31.77%，较上年减少1.27个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622596338","title":"百奥赛图(688796.SH)：2025年归母净利润1.73亿元，同比增加416.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622596338","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622596338?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:37","pubTimestamp":1774521425,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨百奥赛图(688796.SH)公布2025年年度报告，报告期内，公司实现营业收入13.79亿元，同比增加40.63%；利润总额1.88亿元，同比增加337.90%；归属于上市公司股东的净利润为1.73亿元，同比增加416.37%。公司2025年度拟不派发现金红利，不进行资本公积转增股本，不送红股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32101701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621051654","title":"港股百奥赛图-B涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621051654","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621051654?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:14","pubTimestamp":1774336484,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月24日，百奥赛图-B(02315.HK)涨超12%，截至发稿，涨12.14%，报54.5港元，成交额1.6亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682503514.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682503514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VXUS","688796","02315","BK4585","BK4588","BK1161","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621105609","title":"港股异动 | 百奥赛图-B(02315)涨超12% 与Moonlight Bio达成战略合作 去年纯利同比预增超四倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2621105609","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621105609?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:58","pubTimestamp":1774335519,"startTime":"0","endTime":"0","summary":"消息面上，3月23日，百奥赛图宣布与总部位于西雅图、深耕前沿细胞疗法的生物技术公司Moonlight Bio, Inc.达成战略合作协议。根据协议条款，百奥赛图将提供针对治疗靶点的全人抗体分子，Moonlight Bio将负责相关细胞疗法的临床前开发工作。此外，百奥赛图此前发布2025年度业绩快报，预计2025年营业收入约为13.79亿元，同比增长40.63%；实现归属于公司所有者的净利润人民币1.73亿元，同比增长416.37%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","BK4588","BK4585","02315","VXUS","BK0216","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162677931","title":"百奥赛图与合作伙伴达成协议，将提供针对治疗靶点的现货抗体结合剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1162677931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162677931?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:02","pubTimestamp":1774267357,"startTime":"0","endTime":"0","summary":"根据合作协议条款，百奥赛图（Biocytogen）将向合作方提供其针对特定治疗靶点的现货抗体结合剂资源。该合作旨在加速药物研发进程，为靶向治疗领域提供高效解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621765703","title":"百奥赛图宣布与Moonlight Bio达成战略合作，利用全人抗体分子库推进细胞疗法开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2621765703","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621765703?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"北京2026年3月23日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司，一家以创新技术驱动新药研发的国际性生物技术公司，今日宣布与总部位于西雅图、深耕前沿细胞疗法的生物技术公司Moonlight Bio, Inc.达成战略合作协议。此次战略合作将利用我们自主研发的货架型全人抗体库，加速针对难治性癌症的创新细胞疗法的开发。\" 根据协议条款，百奥赛图将提供针对治疗靶点的全人抗体分子，Moonlight Bio将负责相关细胞疗法的临床前开发工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4916326_ZH16326_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK0216","02315","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619458913","title":"百奥赛图-B盘中涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458913","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619458913?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:00","pubTimestamp":1773648022,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月16日，百奥赛图-B(02315.HK)盘中涨超7%，截至发稿涨5.9%，报57.45港元，成交额3372.77万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603163673093149.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673093149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","688796","BK0216","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619430152","title":"港股异动 | 百奥赛图-B(02315)盘中涨超7% 预计全年纯利同比增超4倍 重磅合作项目顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2619430152","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619430152?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:47","pubTimestamp":1773647247,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B(02315)盘中涨超7%，截至发稿，涨5.9%，报57.45港元，成交额3372.77万港元。消息面上，百奥赛图此前发布2025年业绩快报，初步会计数据显示，该公司2025年营收约13.79亿元，实现归母净利1.73亿元，分别同比增长40.63%、416.37%。此外，公司授权IDEAYA的B7H3/PTK7 ADC候选药物IDE034完成1期临床试验首例患者入组，IDEAYA将向公司支付500万美元里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","BK1161","BK0216","BK4585","VXUS","688796","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618604640","title":"港股医药股多数走强 百奥赛图涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604640","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618604640?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:04","pubTimestamp":1773108266,"startTime":"0","endTime":"0","summary":"南方财经3月10日电，港股医药股多数走强，截至发稿，百奥赛图-B(02315.HK)涨9.82%、科伦博泰生物-B(06990.HK)涨9.63%、科济药业-B(09939.HK)涨8.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667195982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","688796","159718"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663819","title":"每周股票复盘：百奥赛图（688796）H股A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663819?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:42","pubTimestamp":1772908932,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，百奥赛图报收于77.5元，较上周的76.75元上涨0.98%。本周，百奥赛图3月6日盘中最高价报77.88元。3月4日盘中最低价报68.17元。百奥赛图当前最新总市值346.35亿元，在医疗服务板块市值排名6/51，在两市A股市值排名616/5190。公司H股和A股的法定/注册股本及已发行股份均无变动。A股于上海证券交易所科创板上市，证券代码688796，上月底结存及本月底结存均为336,116,500股，每股面值人民币1元。公司确认已符合香港联交所规定的公众持股量要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796","159982","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617068725","title":"港股异动 | 百奥赛图-B(02315)涨超8% 预计25年归母净利同比增超4.16倍 商业化提速打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2617068725","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617068725?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:27","pubTimestamp":1772764049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超8%，截至发稿，涨8.15%，报48.86港元，成交额1920.34万港元。消息面上，近日，百奥赛图-B发布2025年度业绩快报，预计集团2025年营业收入约为13.79亿元同比增长40.63%；实现归属于本公司所有者的净利润人民币1.73亿元，同比增长416.37%；实现归属于本公司所有者的扣除非经常性损益的净利润人民币1.16亿元，同比增长405.39%。该行认为，随着授权项目数增加及临床进展推进，抗体开发业务业绩弹性将加速释放，打开公司长期成长空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VT","BK4585","688796","02315","BK1161","VXUS","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616753361","title":"百奥赛图（688796）披露证券变动月报表，3月4日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616753361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616753361?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:13","pubTimestamp":1772615629,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，百奥赛图报收于69.69元，较前一交易日下跌0.43%，最新总市值为311.44亿元。该股当日开盘69.0元，最高70.68元，最低68.17元，成交额达8249.1万元，换手率为3.32%。近日，百奥赛图（北京）医药科技股份有限公司披露《证券变动月报表》，提交截至2026年2月28日的股份变动情况。公告显示，公司H股和A股的法定/注册股本及已发行股份均无变动。公司确认已符合香港联交所规定的公众持股量要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400030016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616184551","title":"每周股票复盘：百奥赛图（688796）2025年净利增416.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616184551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616184551?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:43","pubTimestamp":1772304190,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，百奥赛图报收于76.75元，较上周的75.6元上涨1.52%。本周，百奥赛图2月26日盘中最高价报79.88元，股价触及近一年最高点。本周关注点来自业绩披露要点：百奥赛图2025年归属净利润同比增长416.37%。公司公告汇总百奥赛图（北京）医药科技股份有限公司发布2025年年度业绩快报，营业总收入137,880.84万元，同比增长40.63%；归属于母公司所有者的净利润17,319.98万元，同比增长416.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173470828","title":"百奥赛图达成临床里程碑：IDEAYA首创B7h3/Ptk7双特异性Top1 ADC药物Ide034完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1173470828","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173470828?lang=zh_cn&edition=full","pubTime":"2026-02-28 08:01","pubTimestamp":1772236877,"startTime":"0","endTime":"0","summary":"百奥赛图宣布达成重要临床进展，其合作伙伴IDEAYA Biosciences研发的首创B7h3/Ptk7双特异性Top1抗体偶联药物Ide034，已顺利完成I期临床试验的首例患者给药。这一里程碑标志着该创新疗法正式进入临床验证阶段，为后续开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775000031428,"stockEarnings":[{"period":"1week","weight":0.1283},{"period":"1month","weight":0.212},{"period":"3month","weight":0.7684},{"period":"6month","weight":2.4865},{"period":"ytd","weight":0.7684}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1667},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥赛图(北京)医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2025-12-10","address":"北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院","registeredCapital":"44689万元","survey":" 百奥赛图(北京)医药科技股份有限公司的主营业务是基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务。公司的主要产品是基因编辑服务、创新模式动物销售、临床前药理药效评价服务、抗体开发、创新药合作研发。公司全面的创新模式动物产品和大规模动物生产与体内外药效研究相结合，可为全球生物技术及大型制药公司客户提供疾病模式动物和体内药理服务。","listedPrice":26.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图,688796,百奥赛图股票,百奥赛图股票老虎,百奥赛图股票老虎国际,百奥赛图行情,百奥赛图股票行情,百奥赛图股价,百奥赛图股市,百奥赛图股票价格,百奥赛图股票交易,百奥赛图股票购买,百奥赛图股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}